Philipp von Landenberg

Learn More
The antiphospholipid syndrome (APS) was described in 1983 as a clinical entity characterized by venous and arterial thrombosis, thrombocytopenia, and recurrent fetal loss. The serological markers of APS are antiphospholipid antibodies (APLA) directed mainly against anionic phospholipids, usually cardiolipin but also phosphatidylserine. Some APLA exhibit(More)
Experimental antiphospholipid syndrome (eAPS) induced by immunization with beta(2)-glycoprotein I (beta(2)-GPI) causes behavioral hyperactivity. We assessed the role of thrombotic and inflammatory perivascular factors and standard APS therapies for CNS manifestations. Groups of mice (n=10 per group) were immunized once with beta(2)-GPI (eAPS) or adjuvant(More)
Children with rheumatic oligo- and polyarthritis frequently establish persistent parvovirus B19 infections, which may be associated with the production of antiphospholipid antibodies. Reported in this paper are the data of five girls with polyarticular rheumatic diseases of different types and persistent parvovirus B19 infection associated in four cases(More)
Several studies indicate a pathogenetic role of T-lymphocytes with specificity for heat shock proteins (HSP) in rheumatoid arthritis (RA). Surprisingly, there are no experimental data for B-lymphocytes with specificity for HSP. To investigate whether B-lymphocytes from rheumatoid synovial tissue show a specificity for HSP 60 we immortalized synovial tissue(More)
Two-hundred ninety five patients with the antiphospholipid syndrome (APS) were studied for the presence of antibodies against six anti-β2GPI-related peptides Abs. The prevalence of a wide spectrum of clinical and laboratory parameters of APS was evaluated in all patients, and correlated with the presence of each anti-β2GPI peptide antibody. The rates of the(More)
1Institute of Clinical Chemistry and Laboratory Medicine, University Medical Centre Mainz, Mainz, Germany; 2Department of Medicine I, University Medical Centre Mainz, Mainz, Germany; 3Department of Medicine II, University Medical Centre Mainz, Mainz, Germany; 4Institute of Immunology, University Medical Centre Mainz, Mainz, Germany; and 5Institute of(More)
Der Morbus Fabry ist die einzige lysosomale Speicherkrankheit, bei welcher 2 verschiedene Präparate (Agalsidase α und β) für die Enzymersatztherapie (EET) verfügbar sind. Wir berichten über einen 14-jährigen Jungen, der unter Agalsidase β Infusionsreaktionen und Verhaltensauffälligkeiten zeigte. Bei drohendem Therapieabbruch erfolgte ein Wechsel auf(More)
Systemic autoimmune diseases are characterized by the presence of antinuclear autoantibodies (ANA). Diluted patient sera are typically used to screen for the presence of ANA by immunfluorescence microscopy with fixed HEp-2 cells. Despite high-quality test kits, reports of different laboratories frequently present controversial results. This article(More)